22nd Century Group logo
22nd Century Group XXII
$ 4.0 3.36%
report update icon

Quarterly report 2026-Q1
added 05-07-2026

22nd Century Group Income Statement 2025-2009 | XXII

Brief overview of financial results at 22nd Century Group

The comparison covers a five-year financial horizon. Revenue reported by 22nd Century Group was $28.1 million at the beginning of the period and $17.6 million at the end. Overall revenue changed by −37.4%, equal to an annualized rate of about −9%. The negative rate indicates weakening core operations.

The five-year change in gross profit reached +414.7%: from $1.4 million to $7.4 million. Cost of revenue developed more favorably than sales, supporting gross profitability. The gross margin was 5.1% at the start and 42.1% at the end. Improving gross profitability strengthens the quality of revenue growth.

EBITDA changed from −17.7 million dollars to −11.1 million dollars (+37.2%). Additional revenue translated efficiently into EBITDA. Comparing the endpoints gives EBITDA margins of −62.8% and −63%. EBITDA as a share of revenue remained steady.

The final result was −19.7 million dollars initially and −5.1 million dollars in the final year. The loss narrowed, although sustainable profitability has not yet returned.

The market value of the business moved from 347 million dollars to 541 thousand dollars, or −99.8%. The market is not yet fully reflecting the fundamental progress.

Conclusion

The current trajectory does not yet confirm a sustainable recovery. The constructive conclusion rests on consistent operating efficiency, improving gross profitability and net-income growth. The overall view is constrained by a weaker market valuation, a low EBITDA margin and weak sales momentum. Further direction will depend on top-line growth, operating profitability, and net income.

Annual Income Statement 22nd Century Group

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009

Market Cap

541 K 1.64 K 1.14 K 11.4 M 483 M 347 M 124 M 290 M 355 M 73.5 M 85.2 M 70.2 M 115 M 26.2 M 14.5 M - -

Shares

184 K 557 9.47 K 12.9 M 156 M 139 M 126 M 124 M 101 M 79.8 M 68.1 M 60 M 43.6 M 30.4 M 26.4 M 12.4 M -

Historical Prices

2.94 2.94 0.12 0.89 3.09 2.2 1.1 2.49 2.8 1.09 1.4 1.65 2.14 0.75 0.42

Net Income

-5.05 M -15.2 M -141 M -59.8 M -5.03 M -19.7 M -26.6 M -7.97 M -13 M -11.6 M -11 M -15.6 M -26.2 M -6.74 M -1.35 M -1.42 M -

Revenue

17.6 M 24.4 M 7.36 M 9.95 M 6.81 M 28.1 M 25.8 M 26.4 M 16.6 M 12.3 M 8.52 M 529 K 7.28 M 18.8 K 1.01 M 49.8 K -

Cost of Revenue

10.2 M 14.3 M 24.9 M 38.7 M 29.5 M 26.7 M 25.8 M 25.5 M 17.3 M 12.7 M 9.1 M 498 K 462 K 68 K - - -

Gross Profit

- - - - - 1.44 M 14.5 K 899 K -708 K -430 K -581 K 30.6 K 6.82 M -49.2 K 594 K - -

Operating Income

-11.6 M -14 M -44.9 M -33.6 M -28.4 M -19.2 M -23.6 M -24 M -13.3 M -11.4 M -12 M -11.8 M 1.81 M -3.24 M -3.76 M -1.1 M -

Interest Expense

-207 K 507 K 9.37 M 55 K 58 K 72 K 56 K 11 K 29.1 K 37.7 K 53 K 7.09 K 749 K - - - -

EBITDA

-11.1 M -13.4 M -44.1 M -30.8 M -27.2 M -17.7 M -21 M -22.7 M -12.4 M -10.5 M -11.4 M -11.3 M 1.96 M -3.05 M -3.58 M -933 K -

Operating Expenses

8.43 M 11.6 M 36.2 M 35.5 M 29.9 M 20.4 M 22.4 M 24.9 M 12.6 M 11 M 11.5 M 11.8 M 5 M 3.19 M 4.35 M - -

General and Administrative Expenses

7.59 M 10.3 M 31.1 M 32.2 M 25.9 M 15 M - 7.66 M 7.12 M 6.19 M 7.76 M 8.79 M 4.11 M 2.21 M 1.79 M 591 K -

All numbers in USD currency

Quarterly Income Statement 22nd Century Group

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

595 K 3.54 M 250 K 1.73 M 31.7 K 4.22 K 2.62 K 23.6 K 2.72 M 1.21 M 878 K 846 K 14.3 M 14 M 12.1 M 163 M 163 M 163 M 155 M 144 M 139 M 139 M 139 M 139 M 138 M 125 M 125 M 125 M 125 M 124 M 124 M 124 M 124 M 101 M 91.6 M 90.7 M 90.7 M 80.4 M 76 M 74 M 71 M 70.8 M 66.6 M 64.2 M 64.1 M 60.1 M 58.7 M 57.6 M 56.9 M 47.4 M 39.8 M 36.3 M 34.3 M 31 M 29.3 M 28 M 27.2 M 27.2 M 27.2 M 23.9 M

Net Income

-3.26 M 5.49 M -3.41 M -4.33 M - -3.76 M -1.11 M -5.74 M - -72.7 M -20.5 M -18.2 M - -13.1 M -11.5 M -8.92 M - -9.44 M -4.17 M -5.03 M -6.4 M -4.22 M -5.06 M -4.03 M -6.2 M -10.2 M -8.04 M -2.07 M -8.92 M 6.3 M -6.74 M 1.39 M -3.74 M -3.32 M -3.36 M -2.62 M -2.75 M -2.68 M -2.9 M -3.25 M -2.86 M -2.76 M -1.29 M -4.12 M -5.59 M -2.72 M -1.97 M -5.32 M - -15.4 M -446 K -2.51 M - -449 K 142 K -2.12 M - -465 K -1.1 M -649 K

Revenue

4.1 M 4.01 M 4.08 M 5.96 M - 5.95 M 7.95 M 6.47 M - 7.87 M 8.05 M 8.93 M - 19.4 M 14.5 M 9.04 M - 7.81 M 8.37 M 6.81 M 7.31 M 7.31 M 6.44 M 7.06 M 7.26 M 6.46 M 5.81 M 6.29 M 7.13 M 6.26 M 6.91 M 6.12 M 5.94 M 4.53 M 3.9 M 2.23 M 3.34 M 3.1 M 2.83 M 3.02 M 2.93 M 2.67 M 2.31 M 616 K 911 64.4 K 16.1 K 448 K - 52.5 K - - - 15.7 K - - - 529 K 155 K 117 K

Cost of Revenue

1.92 M 2.56 M 2.86 M 2.88 M - 3.1 M 3.87 M 4.21 M - 3.92 M 4.68 M 4.72 M - 18.8 M 13.6 M 8.74 M - 7.52 M 7.92 M 6.16 M - 6.95 M 6.23 M 6.77 M - 6.48 M 5.9 M 6.4 M - 6.11 M 6.75 M 6.04 M - 4.87 M 4.06 M - - - - - - 2.95 M - - - 306 K - - - 20.6 K - - - - - - - - - -

Gross Profit

- - - - - - - - - - - - - - - - - - - - - - - 287 K 225 K -21.1 K -86.3 K -103 K 515 K 151 K 162 K 71.6 K 71.4 K -340 K -165 K -274 K -228 K -185 K -141 K 124 K 10.8 K -281 K -293 K -16.4 K -806 -241 K 2.94 K 270 K - 32 K - - - - - - - - - -

Operating Income

-3.04 M -3.21 M -2.98 M -2.57 M - -3.38 M -2.05 M -4.43 M - -8.25 M -12 M -10.4 M - -15.3 M -10.5 M -8.15 M - -7.57 M -6.64 M -5.17 M -6.25 M -4.04 M -4.75 M -4.14 M -5.55 M -7.61 M -5.03 M -5.38 M -5.8 M -6.21 M -7.04 M -4.97 M -3.77 M -3.27 M -3.28 M -2.97 M -2.73 M -2.6 M -2.83 M -3.23 M -2.83 M -2.75 M -2.35 M -4.12 M -5.72 M -2.82 M -2.04 M -1.19 M - -1.09 M -1.62 M -1.39 M - -633 K -1.37 M -447 K - -766 K -1.09 M -638 K

Interest Expense

-162 K -33 K -12 K -162 K - 100 K 339 K 1.02 M - 1.27 M -613 K 328 K - 148 K 77 K 5 K - 23 K 14 K 7 K - 23 K 19 K 12 K - 12 K 13 K 11 K - 4.43 K - - - 6.98 K 7.64 K 7.92 K - 9.32 K 9.32 K 10.4 K - 8.7 K 13.8 K 5.51 K - 1.79 K 1.77 K 1.75 K - - - - - - - - - - - -

EBITDA

-2.93 M -3.09 M -2.86 M -2.47 M - -3.23 M -1.9 M -4.33 M - -8.08 M -11.9 M -10.2 M - -15.1 M -10.3 M -7.98 M - -7.4 M -6.49 M -5.03 M -6.25 M -3.88 M -4.6 M -3.87 M -5.55 M -7.45 M -4.88 M -5.09 M -5.8 M -5.35 M -6.5 M -4.7 M -3.77 M -2.65 M -2.87 M -2.77 M -2.73 M -2.05 M -2.47 M -3.05 M -2.83 M -2.25 M -2.02 M -3.96 M -5.72 M -2.5 M -1.84 M -1.12 M - -914 K -1.57 M -1.34 M - -582 K -1.32 M -401 K - -721 K -1.04 M -594 K

Operating Expenses

2.4 M 2.15 M 2.35 M 1.96 M - 2.79 M 2.62 M 3.3 M - 8.33 M 11.1 M 10.4 M - 15.9 M 11.4 M 8.46 M - 7.86 M 7.09 M 5.82 M - 4.4 M 4.95 M 4.43 M - 7.58 M 4.94 M 5.28 M - 6.36 M 7.2 M 5.04 M - 2.93 M 3.12 M 2.7 M - 2.41 M 2.69 M 3.35 M - 2.48 M 2.06 M 4.11 M - 2.58 M 2.04 M - - - - - - - - - - - - -

General and Administrative Expenses

2.12 M 1.85 M 2.12 M 1.8 M - 2.55 M 2.36 M 2.91 M - 6.94 M 10.3 M 9.84 M - 14.5 M 8.68 M 7.26 M - 6.83 M 6.18 M 4.83 M - 3.17 M 3.5 M 3.14 M - 4.06 M 2.37 M 2.24 M - 1.76 M 1.91 M 2.03 M - 1.64 M 1.81 M 1.62 M - 1.23 M 1.72 M 1.85 M - 1.3 M 1.3 M 3.65 M - 1.81 M 1.34 M 1.01 M - 908 K 1.4 M 1.15 M - 370 K 1.05 M 310 K - 451 K 604 K 326 K

All numbers in USD currency

The income statement is one of the three key financial reports of a company 22nd Century Group (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
Cullinan Management Cullinan Management
CGEM
$ 16.5 -5.82 % $ 994 M usaUSA
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
Heron Therapeutics Heron Therapeutics
HRTX
$ 0.5 -0.24 % $ 83.4 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
- - $ 2.18 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
INmune Bio INmune Bio
INMB
$ 1.75 -1.13 % $ 43.3 M usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited
ASLN
- -14.27 % $ 1.7 M singaporeSingapore
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Mirum Pharmaceuticals Mirum Pharmaceuticals
MIRM
$ 105.95 -5.9 % $ 5.32 B usaUSA
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
MannKind Corporation MannKind Corporation
MNKD
$ 3.91 -4.87 % $ 1.2 B usaUSA
MediciNova MediciNova
MNOV
$ 1.33 -0.75 % $ 65.3 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
IMV IMV
IMV
- - $ 13.1 M canadaCanada
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Freeline Therapeutics Holdings plc Freeline Therapeutics Holdings plc
FRLN
- - $ 384 M britainBritain
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
GlycoMimetics GlycoMimetics
GLYC
- 9357.83 % $ 1.01 B usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA